Table 2. Open in new tab Independent...

	Progression-Free Survival				Overall Survival
A
CDKN2A	.0950	.3837	1.40	0.94–2.07	.0215	.0430	1.57	1.07–2.32
CDKN2B	.1960	.3847	1.28	0.88–1.85	.0039	.0120	1.74	1.19–2.53
EGFR	.1648	.3847	1.30	0.90–1.88	.0010	.0100	1.85	1.28–2.68
NF1	.2656	.3847	1.29	0.82–2.03	.4850	.5389	0.85	0.53–1.35
PDGFRA	.9788	.9788	1.01	0.54–1.88	.7427	.7427	1.10	0.61–1.99
PIK3CA	.5273	.6292	1.18	0.70–2.00	.3403	.4254	1.28	0.77–2.12
PTEN	.5663	.6292	0.90	0.62–1.29	.0295	.0492	0.66	0.46–0.96
TERT promoter	.1151	.3837	1.63	0.89–2.99	.0048	.0120	2.49	1.32–4.70
TP53	.2693	.3847	0.80	0.54–1.19	.2097	.2996	0.77	0.52–1.16
IDH1/2	.0171	.1710	0.33	0.14–0.82	.0044	.0120	0.12	0.03–0.52
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR
B
CDKN2A	.1307	.6304	1.35	0.91–2.00	.0320	.0720	1.53	1.04–2.26
CDKN2B	.2154	.6304	1.26	0.87–1.83	.0028	.0185	1.78	1.22–2.61
EGFR	.3467	.6304	1.20	0.82–1.73	.0062	.0186	1.67	1.16–2.42
NF1	.3502	.6304	1.24	0.79–1.95	.3586	.5379	0.80	0.51–1.28
PDGFRA	.9915	.9915	1.00	0.54–1.87	.7030	.7030	1.12	0.62–2.02
PIK3CA	.5504	.8033	1.17	0.69–1.99	.4359	.5604	1.23	0.73–2.04
PTEN	.2441	.6304	0.80	0.56–1.16	.0041	.0185	0.58	0.40–0.84
TERT promoter	.6248	.8033	1.18	0.62–2.25	.1234	.2221	1.67	0.87–3.22
TP53	.7233	.8137	0.93	0.62–1.40	.6888	.7030	0.92	0.62–1.37
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR, IDH1/2 mutation

Progression-Free Survival

Overall Survival

Gene mutation

FDR-adjusted P value

95% CI

P value

FDR-adjusted P value

95% CI

CDKN2A

.0950

.3837

1.40

0.94–2.07

.0215

.0430

1.57

1.07–2.32

CDKN2B

.1960

.3847

1.28

0.88–1.85

.0039

.0120

1.74

1.19–2.53

EGFR

.1648

.3847

1.30

0.90–1.88

.0010

.0100

1.85

1.28–2.68

NF1

.2656

.3847

1.29

0.82–2.03

.4850

.5389

0.85

0.53–1.35

PDGFRA

.9788

1.01

0.54–1.88

.7427

1.10

0.61–1.99

PIK3CA

.5273

.6292

1.18

0.70–2.00

.3403

.4254

1.28

0.77–2.12

PTEN

.5663

.6292

0.90

0.62–1.29

.0295

.0492

0.66

0.46–0.96

TERT promoter

.1151

.3837

1.63

0.89–2.99

.0048

.0120

2.49

1.32–4.70

TP53

.2693

.3847

0.80

0.54–1.19

.2097

.2996

0.77

0.52–1.16

IDH1/2

.0171

.1710

0.33

0.14–0.82

.0044

.0120

0.12

0.03–0.52

Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR

CDKN2A

.1307

.6304

1.35

0.91–2.00

.0320

.0720

1.53

1.04–2.26

CDKN2B

.2154

.6304

1.26

0.87–1.83

.0028

.0185

1.78

1.22–2.61

EGFR

.3467

.6304

1.20

0.82–1.73

.0062

.0186

1.67

1.16–2.42

NF1

.3502

.6304

1.24

0.79–1.95

.3586

.5379

0.80

0.51–1.28

PDGFRA

.9915

1.00

0.54–1.87

.7030

1.12

0.62–2.02

PIK3CA

.5504

.8033

1.17

0.69–1.99

.4359

.5604

1.23

0.73–2.04

PTEN

.2441

.6304

0.80

0.56–1.16

.0041

.0185

0.58

0.40–0.84

TERT promoter

.6248

.8033

1.18

0.62–2.25

.1234

.2221

1.67

0.87–3.22

TP53

.7233

.8137

0.93

0.62–1.40

.6888

.7030

0.92

0.62–1.37

Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR, IDH1/2 mutation

	Progression-Free Survival				Overall Survival
A
CDKN2A	.0950	.3837	1.40	0.94–2.07	.0215	.0430	1.57	1.07–2.32
CDKN2B	.1960	.3847	1.28	0.88–1.85	.0039	.0120	1.74	1.19–2.53
EGFR	.1648	.3847	1.30	0.90–1.88	.0010	.0100	1.85	1.28–2.68
NF1	.2656	.3847	1.29	0.82–2.03	.4850	.5389	0.85	0.53–1.35
PDGFRA	.9788	.9788	1.01	0.54–1.88	.7427	.7427	1.10	0.61–1.99
PIK3CA	.5273	.6292	1.18	0.70–2.00	.3403	.4254	1.28	0.77–2.12
PTEN	.5663	.6292	0.90	0.62–1.29	.0295	.0492	0.66	0.46–0.96
TERT promoter	.1151	.3837	1.63	0.89–2.99	.0048	.0120	2.49	1.32–4.70
TP53	.2693	.3847	0.80	0.54–1.19	.2097	.2996	0.77	0.52–1.16
IDH1/2	.0171	.1710	0.33	0.14–0.82	.0044	.0120	0.12	0.03–0.52
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR
B
CDKN2A	.1307	.6304	1.35	0.91–2.00	.0320	.0720	1.53	1.04–2.26
CDKN2B	.2154	.6304	1.26	0.87–1.83	.0028	.0185	1.78	1.22–2.61
EGFR	.3467	.6304	1.20	0.82–1.73	.0062	.0186	1.67	1.16–2.42
NF1	.3502	.6304	1.24	0.79–1.95	.3586	.5379	0.80	0.51–1.28
PDGFRA	.9915	.9915	1.00	0.54–1.87	.7030	.7030	1.12	0.62–2.02
PIK3CA	.5504	.8033	1.17	0.69–1.99	.4359	.5604	1.23	0.73–2.04
PTEN	.2441	.6304	0.80	0.56–1.16	.0041	.0185	0.58	0.40–0.84
TERT promoter	.6248	.8033	1.18	0.62–2.25	.1234	.2221	1.67	0.87–3.22
TP53	.7233	.8137	0.93	0.62–1.40	.6888	.7030	0.92	0.62–1.37
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR, IDH1/2 mutation

Table 2.

Open in new tab

Independent Prognostic Value of a Subset of Commonly Mutated Genes Using Multivariate Analysis and Multiple Comparisons (N = 185)

	Progression-Free Survival				Overall Survival
Gene mutation	P	FDR-adjusted P value	HR	95% CI	P value	FDR-adjusted P value	HR	95% CI
A
CDKN2A	.0950	.3837	1.40	0.94–2.07	.0215	.0430	1.57	1.07–2.32
CDKN2B	.1960	.3847	1.28	0.88–1.85	.0039	.0120	1.74	1.19–2.53
EGFR	.1648	.3847	1.30	0.90–1.88	.0010	.0100	1.85	1.28–2.68
NF1	.2656	.3847	1.29	0.82–2.03	.4850	.5389	0.85	0.53–1.35
PDGFRA	.9788	.9788	1.01	0.54–1.88	.7427	.7427	1.10	0.61–1.99
PIK3CA	.5273	.6292	1.18	0.70–2.00	.3403	.4254	1.28	0.77–2.12
PTEN	.5663	.6292	0.90	0.62–1.29	.0295	.0492	0.66	0.46–0.96
TERT promoter	.1151	.3837	1.63	0.89–2.99	.0048	.0120	2.49	1.32–4.70
TP53	.2693	.3847	0.80	0.54–1.19	.2097	.2996	0.77	0.52–1.16
IDH1/2	.0171	.1710	0.33	0.14–0.82	.0044	.0120	0.12	0.03–0.52
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR
B
CDKN2A	.1307	.6304	1.35	0.91–2.00	.0320	.0720	1.53	1.04–2.26
CDKN2B	.2154	.6304	1.26	0.87–1.83	.0028	.0185	1.78	1.22–2.61
EGFR	.3467	.6304	1.20	0.82–1.73	.0062	.0186	1.67	1.16–2.42
NF1	.3502	.6304	1.24	0.79–1.95	.3586	.5379	0.80	0.51–1.28
PDGFRA	.9915	.9915	1.00	0.54–1.87	.7030	.7030	1.12	0.62–2.02
PIK3CA	.5504	.8033	1.17	0.69–1.99	.4359	.5604	1.23	0.73–2.04
PTEN	.2441	.6304	0.80	0.56–1.16	.0041	.0185	0.58	0.40–0.84
TERT promoter	.6248	.8033	1.18	0.62–2.25	.1234	.2221	1.67	0.87–3.22
TP53	.7233	.8137	0.93	0.62–1.40	.6888	.7030	0.92	0.62–1.37
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR, IDH1/2 mutation

	Progression-Free Survival				Overall Survival
Gene mutation	P	FDR-adjusted P value	HR	95% CI	P value	FDR-adjusted P value	HR	95% CI
A
CDKN2A	.0950	.3837	1.40	0.94–2.07	.0215	.0430	1.57	1.07–2.32
CDKN2B	.1960	.3847	1.28	0.88–1.85	.0039	.0120	1.74	1.19–2.53
EGFR	.1648	.3847	1.30	0.90–1.88	.0010	.0100	1.85	1.28–2.68
NF1	.2656	.3847	1.29	0.82–2.03	.4850	.5389	0.85	0.53–1.35
PDGFRA	.9788	.9788	1.01	0.54–1.88	.7427	.7427	1.10	0.61–1.99
PIK3CA	.5273	.6292	1.18	0.70–2.00	.3403	.4254	1.28	0.77–2.12
PTEN	.5663	.6292	0.90	0.62–1.29	.0295	.0492	0.66	0.46–0.96
TERT promoter	.1151	.3837	1.63	0.89–2.99	.0048	.0120	2.49	1.32–4.70
TP53	.2693	.3847	0.80	0.54–1.19	.2097	.2996	0.77	0.52–1.16
IDH1/2	.0171	.1710	0.33	0.14–0.82	.0044	.0120	0.12	0.03–0.52
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR
B
CDKN2A	.1307	.6304	1.35	0.91–2.00	.0320	.0720	1.53	1.04–2.26
CDKN2B	.2154	.6304	1.26	0.87–1.83	.0028	.0185	1.78	1.22–2.61
EGFR	.3467	.6304	1.20	0.82–1.73	.0062	.0186	1.67	1.16–2.42
NF1	.3502	.6304	1.24	0.79–1.95	.3586	.5379	0.80	0.51–1.28
PDGFRA	.9915	.9915	1.00	0.54–1.87	.7030	.7030	1.12	0.62–2.02
PIK3CA	.5504	.8033	1.17	0.69–1.99	.4359	.5604	1.23	0.73–2.04
PTEN	.2441	.6304	0.80	0.56–1.16	.0041	.0185	0.58	0.40–0.84
TERT promoter	.6248	.8033	1.18	0.62–2.25	.1234	.2221	1.67	0.87–3.22
TP53	.7233	.8137	0.93	0.62–1.40	.6888	.7030	0.92	0.62–1.37
Covariates: age, KPS, adjuvant chemoradiation, MGMT promoter methylation, EOR, IDH1/2 mutation

Bolded values indicate P < .05.

This Feature Is Available To Subscribers Only